Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Discontinuation of iv bapineuzumab places solanezumab under scrutiny

This article was originally published in Scrip

Executive Summary

Having failed to meet its co-primary endpoints in the second of four Phase III trials, development of iv bapineuzumab in Alzheimer's disease has been abandoned. Discontinuation of this eagerly anticipated candidate will reignite debate surrounding the appropriateness of targeting beta amyloid in cases where plaques are already present, and shine the spotlight firmly on Lilly's solanezumab, says Datamonitor's Charlotte Mackey.

You may also be interested in...



Potential first-to-market long acting levodopa combo from Impax/GSK shows promise in PD

Impax and GlaxoSmithKline have announced that IPX066 has demonstrated a statistically significant improvement over carbidopa-levodopa plus entacapone in reducing the percentage of “off-time” in the ASCEND-PD Phase III trial of Parkinson’s disease patients (Scripintelligence.com, 15 August, 2011). The strength of the extended release cabidopa-levodopa formulation lies in its increased "off time" compared to immediate-release formulations, reduced motor symptoms, and less frequent administration. However, the pricing strategy for IPX066 will have a critical bearing on the drug’s commercial success.

Topics

Related Companies

UsernamePublicRestriction

Register

SC018401

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel